Ceftaroline fosamil
- Generic Name
- Ceftaroline fosamil
- Brand Names
- Teflaro, Zinforo
- Drug Type
- Small Molecule
- Chemical Formula
- C22H21N8O8PS4
- CAS Number
- 229016-73-3
- Unique Ingredient Identifier
- 7P6FQA5D21
- Background
Ceftaroline fosamil is a cephalosporin antibacterial indicated for the treatment of the following infections caused by designated susceptible bacteria:
Acute bacterial skin and skin structure infections.
Community-acquired bacterial pneumonia.
- Indication
Ceftaroline fosamil is indicated for the treatment of patients with the following infections caused by susceptible isolates of the designated microorganisms.
- Associated Conditions
- Acute Bacterial Skin and Skin Structure Infection (ABSSSI), Community-Acquired Bacterial Pneumonia (CABP)
- Associated Therapies
- -
Orchid AMS eyes Rs 300 cr turnover in 3 years for antimicrobial resistance
Orchid Pharma's new antimicrobial solutions division, Orchid AMS, aims to achieve a turnover of up to Rs 300 crore in three years with 250 salespeople, targeting 2,500-3,000 hospitals for antimicrobial stewardship programmes. The division will roll out 30 molecules, led by Orblicef, to combat antimicrobial resistance in India.
Orchid Pharma announces national launch of antimicrobial solutions division
Orchid Pharma forms Orchid AMS to combat Antimicrobial Resistance in India through innovative products, support programs, and digital solutions, aiming to partner with 2,500-3,000 hospitals for effective antimicrobial stewardship.
Orchid Pharma announces National Launch of Orchid AMS division, to combat the rising ...
Orchid Pharma forms Orchid AMS to combat AMR in India, targeting 3000 hospitals with innovative solutions. The unit will engage healthcare communities in 13 cities, focusing on pathbreaking products, evidence-based recommendations, and digital solutions for doctors.
Orchid Pharma sets up Orchid AMS division, to combat the rising threat of antimicrobial resistance
Orchid Pharma forms Orchid AMS to combat antimicrobial resistance in India, focusing on innovative products, support programs, and digital solutions. The new division aims to partner with 2,500-3,000 hospitals to implement antimicrobial stewardship programs and will lead discussions on AMR in key cities. Orchid AMS will introduce path-breaking products like Orblicef and collaborate with hospitals to strengthen stewardship practices, providing real-time data on resistance patterns.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath